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J. Michaels*Department of Vascular Surgery, University of Sheffield, Sheffield, UKOver the past 10 years, there has been a rapid
development in techniques for the endovascular
repair of abdominal aortic aneurysms (EVAR). A
mixed picture is emerging from the growing evi-
dence-base, which includes recent publications of the
medium term results of large registries,1,2 the first
reports of randomised controlled trials (RCTs)3,4 and a
systematic literature review that includes nearly
20,000 reported cases of EVAR.5
The investigation of new technologies and
interpretation of early published evidence raise a
number of difficulties. Early results may suffer from
publication bias tending to emphasise positive out-
comes and, due to the desire for rapid publication,
concentrating on short-term results. Early technology
is unstable and continues to evolve, with many
prototype devices being superceded by the time that
results are published. Those carrying out the pro-
cedures may have a steep learning curve and the
relevant population for the procedure may not have
been clearly defined, leading to a lack of comparable
case-mix in early-published series. There are also
specific issues around the comparison of procedures
where one is far less invasive than another, making it
difficult to recruit patients to randomised controlled
trials or causing confounding through high rates of
crossover between the arms of the trial.
Finally, there are conflicting pressures from con-
sumers keen to adopt new and minimally invasive
techniques, healthcare providers who wish to ensure
value for money and commercial concerns, keen to get
an early return on the considerable investment that is
required in the new technology.
Given these difficulties it is heartening to see recent
major publications from the two UK EVAR trials,
providing high quality medium term data relating toing author. Prof Jonathan Michaels, Department of
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to be congratulated on a considerable achievement.
The two trials consider different clinical circumstances
with EVAR 1 comparing the procedure with open
repair in a fit population6 and EVAR 2 comparing it
with best medical management in those considered
unfit for surgery.7
So where do we currently stand with regard to the
evidence on EVAR, and howmight we move forward?
As might be expected, there are clear early benefits
with lower procedure-related mortality following
EVAR. The initial results of the EVAR 1 trial reported
a significant reduction in 30-day mortality from 4.7%
for open repair to 1.7% for EVAR,3 and this was
consistent with the mortality benefit seen in the
DREAM trial4 and with the collected non-randomised
comparisons in the systematic review.5 Meta-analysis
from the review suggests a significant benefit, with an
odds ratio of 0.33 (CI 0.26–0.42) for 30-day mortality
following EVAR as compared with open surgical
repair. The evidence that EVAR has a mortality that
is about a third of that seen following conventional
repair is enough to boost demand for the procedure,
but may lead to future difficulties in randomising a
population that is being offered an invasive treatment
for a condition that is usually asymptomatic.
In those who are unfit for surgical repair the
registries suggest a much higher initial procedure-
related mortality and the RCT evidence of the EVAR 2
trial estimates the 30-day mortality to be 9%, which is
in keeping with the subgroup analysis from the RETA
registry.1 Although this figure may seem relatively
high it is within the range of reported mortality
following open repair8 and may be justified in a
population with a significant risk of death from
aneurysm rupture.
However, the procedure is a prophylactic one with
the benefit depending upon how well it protects
against the risks of untreated aneurysm, and this isEur J Vasc Endovasc Surg 30, 115–118 (2005)
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from the randomised controlled trials have failed to
show overall survival advantages and all the evidence
demonstrates a significant rate of endoleak and late
aneurysm expansion, with the need for continuing
surveillance and re-intervention. The EVAR 1 trial
showed a rate of re-intervention of 6.9 per 100 patient
years following EVAR compared with 2.4 following
open repair and overall complication rates were 17.6
vs. 3.3 per 100 patient years. The trial results suggest
that the higher complication rate and increased need
for re-intervention persist in the medium term and are
not restricted to the early period following the
procedure. One can argue about whether this is a
teething problem of the new technology that will be
eliminated as new generations of device are developed
or whether it is a fundamental limitation of the current
fixation techniques that will require changes to the
way that devices are introduced or held in place.
However, with consistent results seen in the recently
published two-year results of the Dutch Randomised
Endovascular Aneurysm Management (DREAM) trial9
and other large non-randomised series, this is the best
current estimate of the likely re-intervention rate.
It might be expected that those patients with co-
morbidities that preclude surgical treatment would be
most likely to benefit from EVAR; however, this has
not been confirmed by the EVAR 2 trial. The high
expected aneurysm related mortality did not occur in
the non-operative arm of the trial and only 23
aneurysm related deaths were reported, a rate of
nine deaths per 100 patient years, approximately
matching the procedure-related mortality. With a
high total mortality of 64% at 4 years there was no
overall survival benefit in the EVAR group. There may
be many reasons for this difference between expected
and observed aneurysm related mortality. Perhaps the
most important is the possibility of an element of
confounding due to crossover of patients on best
medical management to exclusion by EVAR or
surgery. Within the trial these patients would have
been under close surveillance and over twice as
many patients (47) underwent late aneurysm repair
as died of aneurysm related causes. Many of these
had enlarging aneurysms or had developed symp-
toms and may have considerably increased the
aneurysm related mortality had such crossovers
not occurred.
It is a necessary drawback of RCTs that data needs
to be aggregated to produce adequate sample size,
whilst in clinical practice estimates of risks and
benefits form a continuum. There are four key
parameters that are likely to determine the overallEur J Vasc Endovasc Surg Vol 30, August 2005balance of risks and benefits in an individual patient
with an aneurysm.
Firstly, there is the risk related to the procedure
itself, which may be partly predicted from physiologi-
cal scoring10 but may also depend on factors specific to
the procedure in question, for example the presence of
a hostile abdomen for open repair or difficulty in
access due to iliac tortuosity for EVAR. Secondly, there
is the estimated long-term survival, which may be
predicted from factors such as age and the presence of
known co-morbidity. The third element is the risk of
aneurysm related death if the aneurysm remains
untreated. This can largely be predicted from aneur-
ysm size but there remains a question, raised by the
EVAR 2 trial, as to the extent to which high-risk
patients can be identified by further surveillance and
managed by delayed intervention. Finally, we need to
understand the factors that predict long term success
following EVAR and it is in this area that we have the
least information. It may well be that with further
experience we will be able to identify factors relating
to patient characteristics, aneurysm morphology and
technical issues that can help to predict the occurrence
of complications and need for further intervention.
Thus, for an individual patient the consideration of
specific risk factors may suggest that the general
messages of the RCTs are not directly applicable, and
yet it would clearly be impossible to carry out further
RCTs covering every possible combination of clinical
situations. Treatment decisions need to make the best
use existing evidence without unjustified extrapol-
ation and generalisation.
Some clear messages emerge from consideration of
the current evidence. The first is that although EVAR
has significant benefits in terms of early mortality
this is offset by an increased need for surveillance and
re-intervention and there remains considerable
uncertainty about any long-term benefits in overall
mortality. For this reason it should still be considered
an experimental procedure and informed consent
must ensure that patients understand all the limi-
tations and uncertainties, as well as the early benefits.
The second message relates to the nature of further
investigation that is required. Whilst it is difficult to
reliably assess the potential cost-effectiveness of new
techniques at such an early stage, the EVAR trials
suggest that there is an excess cost of about £3300 per
patient compared to open repair and £8600 compared
to non-operative treatment. The latter may well be a
considerable underestimate of the true cost due to the
high crossover rate within the trial. Economic model-
ling based on the best evidence that is currently
available11 suggests that for the procedure to be cost-
effective would require a significant reduction in the
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research needs to be the identification of develop-
ments in devices, operator skills and aspects of patient
selection that will make it possible to minimise the rate
of late complications and the need for re-intervention.
In this respect there are already potential technical
advances such as supra-renal fixation, combined
laparoscopic and endovascular approaches and the
use of fenestrated grafts that have not been assessed in
the existing trials. Technology is developing rapidly
and one can envisage many further developments
over the next few years in areas such as graft materials,
fixation techniques, endovascular suturing devices,
sealants, introduction methods and monitoring, which
may all have potential to reduce the risk of endoleak,
migration or other complications.
There are clearly more unanswered than answered
questions and the continued scientific evaluation of
EVAR will provide many challenges and require a
range of scientific approaches. Whilst randomised
controlled trials remain the ‘gold standard’ it is
possible that with the dissemination of the evidence
of early survival benefits it will become increasingly
difficult to randomise patients in further trials. Even
where such trials are feasible, the considerable delays
inherent in planning, funding and undertaking them
maymake it difficult to keep up with a rapidly moving
field of technology. Alternative trial designs, such as
‘tracker trials’12 may have the flexibility to allow for
developing technology and shifting areas of equipoise.
However, in practice, it is likely that the vast majority
of procedures will occur outside such trials.
Registries have provided a rich source of evidence
that has helped to inform device development and
assisted with early planning of RCTs. Continuation of
the collection of such data is likely to provide the most
effective way of monitoring progress in the develop-
ment of devices and techniques, and in identifying
sub-groups and situations in which further RCTs are
appropriate. However, given the voluntary nature of
previous registries, the need for accurate long-term
data and the resources required to maintain and
validate these, there must be concerns that these will
fail to provide adequate data without some form of
compulsion or incentive to participate. In some
countries there is the potential for a regulatory body
to place conditions on the use of new procedures, and
when the procedure was considered in 2003 by the
National Institute for Health and Clinical Excellence in
the UK it recommended that EVAR was only carried
out with as part of clinical trials or with appropriate
data submission to a registry.13 It will be interesting to
see the conclusion when they reconsider the procedure
in the light of the EVAR trial results.Finally, there is the issue of how best to use existing
and emerging evidence to inform clinical and manage-
rial decision making. The patient with high risk for
surgery due to a hostile abdomen presents very
different issues from those with severe cardio-respir-
atory disease or advanced malignancy. Whilst RCT
data may be difficult to extrapolate to individual
situations, decision-making can be supported by
predictive modelling using data from a variety of
sources, such as registries and RCT sub-group
analysis. With increasing demand for minimally
invasive treatment it is likely that EVAR is here to
stay. All clinicians undertaking the procedure have a
duty to ensure that individual patients can participate
in informed decision-making using the most appli-
cable estimates of the risks and benefits, and that
future patients can benefit from the continued
collection of high quality data to supplement the
available information.References
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